Volume 24, Issue 104, July - August, 2020

The role of continuous maintenance therapy with pemetrexed in non-squamous non-small cell advanced lung cancer: A prospective cohort study in Vietnam

Nguyen Thi Thai Hoa¹, Nguyen Tien Chung², Huynh Quang Huy^3♦

¹Department of Internal Medicine, Vietnam National Cancer Hospital, Ha Noi, Vietnam.
²Department of Internal Medicine, University of Traditional Medicine, Ha Noi, Vietnam.
³Department of Radiology, Pham Ngoc Thach University of Medicine, Ho Chi Minh city, Vietnam; ORCID ID: https://orcid.org/0000- 0001-5177-1460

^♦Corresponding author
Department of Radiology, Pham Ngoc Thach University of Medicine, Ho Chi Minh city, Vietnam; Email: huyhq@pnt.edu.vn

ABSTRACT

Aims: To evaluate overall survival (OS) and progression- free survival (PFS) of patients with advanced - stage non-squamous nonsmall- cell lung cancer who were treated pemetrexed as maintenance therapy after first-line treatment by pemetrexed- cisplatin. Method: Fifty-one patients with advanced Nonquamous Non-small-cell Lung cancer underwent first-line combination chemotherapy. When initial disease control had been achieved, these patients were received Pemetrexed as continuous maintenance (500mg/m2, on day 1 of the 21-day cycle) at National Cancer Hospital. The primary endpoint of this study was overall survival. Results: Median OS was 16.1 months; Median PFS was 7.8 months. Patients having a partial response to first-line treatment have median OS was 22.8 months, median PFS 9.8 months. Group of patients having a stable disease to first-line treatment has median OS was 13.6 month, median PFS 6.6 months. Conclusion: Our finding shows that pemetrexed maintenance therapy was effective in prolonging OS, PFS in patients with advanced non-squamous non-small-cell lung cancer after treatment pemetrexed- cisplatin.

Keywords: maintenance, pemetrexed, non-small cell lung

Medical Science, 2020, 24(104), 1930-1935

PDF